Eric A. Toth

This paper develops a nanoparticle vaccine platform incorporating native HCV E1E2 to enhance immunogenicity, showing improved neutralizing antibody responses compared to subunit vaccines.

This study identifies the conserved bridging domain on HCV E1E2 as a target for neutralizing antibodies from diverse lineages, showing additivity with neutralizing face antibodies.

This study generates glycoengineered recombinant alpha1-antitrypsin with in vitro and in vivo activities comparable to plasma-derived A1AT, offering a sustainable therapeutic alternative.

The paper designs, characterizes, and tests a soluble HCV E1E2 heterodimer and self-assembling nanoparticles for vaccine development.

This paper shows how substrate specificity in a designed RAS-targeting protease is linked to active site and distal motions, revealing mechanisms for enhanced specificity.

The paper isolates E1-dependent broadly neutralizing antibodies against HCV and uses mAbClust with AlphaFold 3 to map a quaternary epitope spanning E1 and E2.

This study shows that B cells in hepatitis C patients retain dysregulated transcriptional profiles after cure, with sustained TNF signaling driving chronic inflammation and loss of protective memory.

The paper identifies protein interactors that enhance the secretion of HCV E1E2 vaccine candidates in glycoengineered CHO cells using a multi-omics approach.

This study shows that glycoengineering of HCV E2 glycoprotein affects antigen biochemical properties and immune response, with some glycans improving neutralization potency.